Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Euroz Hartleys Healthcare Conference 2024
12 slides from Pyc Therapeutics's conference presentation, Feb 6, 2024
Slide 1: Euroz Hartleys Healthcare Conference Presentation
6 February 2024 EUROZ HARTLEYS HEALTHCARE CONFERENCE PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 6 February 2024 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC’s CEO, Dr Rohan Hockings, at the Euroz Hartleys Healthcare
Slide 2: For personal use only
This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. This ASX announcement was approved and authorised for
Slide 3: Life-changing science
For personal use only Life-changing science Euroz-Hartleys Healthcare Conference February 2024
Slide 4: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the factors, many of which are outside PYC’s control. Important factors For personal use only business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides that could cause actual results to differ materially from assumpti
Slide 5: Today's topics
Today’s topics • Introduction to PYC For personal use only • PYC’s drug candidates are effective in patient-derived models • Patient-derived models are the best predictor of success in human trials • PYC is now in human trials establishing both safety and efficacy • Success in these human studies wi
Slide 6: PYC Therapeutics
PYC Therapeutics For personal use only • PYC is a precision medicine company progressing a pipeline of best-in-class drug candidates towards major unmet patient needs • Each drug candidate represents a significant commercial opportunity • In 2024, PYC will begin to generate the human safety and effi
Slide 7: PYC has multiple assets progressing towards major unmet patient needs
PYC has multiple assets progressing towards major unmet patient needs For personal use only Historical progress Progress expected within 12 months PROGRAM PRE-CLINICAL CLINICAL TRIALS MARKETED VP-001* Retinitis Pigmentosa Type 11 PYC-003 Polycystic Kidney Disease PYC-001 Autosomal Dominant Optic Atr
Slide 8: 'Mini-organs' derived from patients provide the greatest insight into clinical trial outcomes
‘Mini-organs’ (‘organoids’) derived from patients provide the greatest insight into outcomes in clinical trials For personal use only “We need to understand as early as possible whether a drug candidate is safe and works in patients, not wait to find out in clinical trials which can be expensive and
Slide 9: PYC's polycystic kidney disease drug candidate is effective in 3D kidney models
PYC’s polycystic kidney disease drug candidate is effective in 3D kidney models derived from patients with end-stage renal failure 3D kidney model For personal use only Polycystic Untreated PYC-003 treated Unaffected kidney kidney 1. See ASX announcement of 13 November 2023 PYC THERAPEUTICS 7
Slide 10: PYC's first blinding eye disease drug has demonstrated efficacy in 'retina-in-a-dish' models
PYC’s first blinding eye disease drug has demonstrated efficacy in ‘retina-in-a-dish’ models derived from patients with the disease For personal use only Unaffected retina Retinitis Pigmentosa (RP) RP + VP-001 treatment 1. See ASX announcement of 19 April 2023 PYC THERAPEUTICS 8
Slide 11: PYC's second blinding eye disease drug has demonstrated efficacy in 'retina-in-a-dish' models
PYC’s second blinding eye disease drug has demonstrated efficacy in ‘retina-in-a-dish’ models derived from patients with the disease Untreated PYC-001 treated For personal use only Fragmented Elongated mitochondria mitochondria in ADOA in ADOA patient retinal patient retinal cells cells treated with
Slide 12: Success in the on-going human trials will see PYC launch multiple best-in-class drugs beginning in 2028
Success in the on-going human trials will see PYC launch multiple best-in- class drugs beginning in 2028 For personal use only Commercialisation² Indication Market size¹ 2028 2029 2030 Retinitis Pigmentosa 11 $1 billion p.a. Polycystic Kidney Disease $10 billion p.a. Optic Atrophy $2 billion p.a. 1.
PYC Therapeutics — Euroz Hartleys Healthcare Conference 2024 on 6ix